Exhale

The official blog of the Lung Institute.

Is Silicosis Fatal?

Is Silicosis Fatal?

Yes, silicosis can be fatal. This respiratory disease is caused by inhaling crystalline silica dust, which produces inflammation and scarring when it settles into the lungs. As time passes, this scarring causes the lungs to stiffen. Silicosis is associated with various symptoms that tend to worsen over time, the most common of which include coughing, difficulty breathing and chest pain. It also increases the risk of developing other serious medical conditions, such as tuberculosis, chronic obstructive pulmonary disease (COPD) and lung cancer. Unfortunately, even with treatment, silicosis may ultimately lead to death.

Although there is currently no cure for silicosis, various treatment options exist that can help patients manage their symptoms and improve their quality of life, including the following:

  • Bronchodilators
  • Inhaled corticosteroids
  • Cough medicine
  • Supplemental oxygen therapy
  • Lifestyle changes (such as changing occupations or quitting smoking)

The Lung Institute also offers an alternative approach to silicosis treatment through cellular therapy. Unlike the above-listed treatment methods, which offer relief from symptoms but have no effect on the underlying condition itself, cellular therapy has the potential to slow the progression of silicosis. Treatment involves a three-step process, consisting of collecting  blood sample from the patient, separating the cells from the rest of the sample and then returning the concentrated cells into the patient’s bloodstream. Once the cells are reintroduced into the patient’s body, they can promote natural healing and help to reduce inflammation within the lungs. Silicosis treatment using cellular therapy is a minimally invasive process that can be completed on an outpatient basis over the course of two days.

If you would like to know more about how cellular therapy can help with the treatment of silicosis, please contact the Lung Institute today at (800) 729-3065. We look forward to helping you breathe easier.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.